Welcome to our dedicated page for PolyPid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd. has begun submitting a New Drug Application to the U.S. FDA for its lead product, D-PLEX₁₀₀, to prevent surgical site infections in patients undergoing colorectal surgery. The NDA is being filed under Fast Track designation, allowing a rolling review, and the first Chemistry, Manufacturing and Controls and nonclinical modules have been submitted, with the clinical section expected in the second quarter of 2026.
D-PLEX₁₀₀ uses PolyPid’s Kynatrix delivery technology to release the antibiotic doxycycline directly at the surgical site over 30 days. In the Phase 3 SHIELD II trial, it achieved a statistically significant 60% relative risk reduction in infection rates after abdominal colorectal surgery and has received Breakthrough Therapy Designation from the FDA. PolyPid is also advancing negotiations for a U.S. commercialization partnership.
PolyPid Ltd. executive Ori Warshavsky, Chief Operating Officer – US, reports his direct holdings of company equity. He holds several employee stock options to buy Ordinary Shares at exercise prices ranging from 2.6700 to 23.0700 per share, with expiration dates from 2031-08-09 through 2035-05-12.
These option grants vest on various quarterly schedules or are already fully vested, as described in the footnotes, and he also directly holds 267 Ordinary Shares.
PolyPid Ltd. director Dror-Darwish Nir reported existing option holdings in a Form 3. The filing lists six stock option grants over Ordinary Shares, with exercise prices ranging from 2.6700 to 23.0700 and expiration dates between 2030 and 2036. Footnotes state that most grants are already fully vested, while one grant made on June 25, 2025 vests quarterly through May 12, 2029.
PolyPid Ltd. Chief Financial Officer Jonathan Missulawin filed an initial ownership report listing multiple employee stock options over Ordinary Shares. These options cover various blocks of shares, including 64,500 underlying shares at an exercise price of 4.6400 and 42,000 underlying shares at 2.6700, with expirations ranging from 2027 to 2035. The filing records existing derivative holdings and does not show any stock purchases or sales.
PolyPid Ltd. director Barenholz Yechezkel reports his initial holdings in a Form 3. The filing shows direct ownership of 2,760 Ordinary Shares and several stock option awards over Ordinary Shares, with exercise prices ranging from $2.6700 to $23.0700 and expirations from 2031 to 2035. Footnotes explain that earlier grants are already fully vested, while a June 25, 2025 grant vests quarterly through May 12, 2029.
PolyPid Ltd. director Joseph BenAmram has reported his initial derivative holdings in company stock options. The Form 3 shows three stock option grants over ordinary shares with different exercise prices and vesting schedules. One grant covers 625 underlying shares at an exercise price of $11.4000 per share, expiring on May 8, 2033, and vests quarterly until May 8, 2026. A second grant covers 6,500 underlying shares at an exercise price of $4.2400, expiring on July 2, 2034, which was fully vested as of July 2, 2025. The third grant covers 14,440 underlying shares at an exercise price of $2.6700, expiring on June 25, 2035, and vests on a quarterly basis beginning May 12, 2025 until May 12, 2029. The filing lists these as direct holdings and does not show any new purchases or sales, only existing option positions.
PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares. The options cover 17,456 underlying Ordinary Shares at an exercise price of $4.01 per share and expire on February 4, 2036. According to the footnote, these options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025, continuing through December 11, 2029.
PolyPid Ltd. director Krinsky Itzhak filed an initial ownership report showing a mix of ordinary shares and stock options. He directly holds 833 Ordinary Shares. He also holds several stock option awards over Ordinary Shares, including 6,500 shares at an exercise price of $4.2400 expiring on July 2, 2034 and 14,440 shares at $2.6700 expiring on June 25, 2035. Additional options cover smaller amounts of shares at exercise prices of $11.4000 and $23.0700 with expiration dates between 2029 and 2033. Footnotes state that most of these options are already fully vested, while the June 25, 2025 grant vests quarterly until May 12, 2029.
PolyPid Ltd. director and Chief Executive Officer Dikla Czaczkes Akselbrad filed an initial ownership report listing her existing equity position in the company. The filing shows direct holdings of 934 Ordinary Shares and multiple stock options to buy additional Ordinary Shares at exercise prices ranging from 92.8900 down to 2.6700 per share, with expiration dates between 2026 and 2035. Several option grants are already fully vested, while others vest on a quarterly basis over future periods, indicating a mix of long-standing and more recent compensation awards rather than new market purchases or sales.
PolyPid Ltd. deputy CEO and EVP R&D Hazan Dalit Fellous has filed an initial Form 3 reporting holdings of employee stock options over the company’s ordinary shares. The filing lists multiple option grants with exercise prices ranging from 2.6700 to 92.8900 per share and expirations between 2026 and 2035.
Several grants are disclosed as fully vested based on earlier grant dates, while others vest on a quarterly schedule through dates such as May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029. This Form 3 records existing derivative holdings and does not show any new purchases or sales.